Pharmacokinetic-Pharmacodynamic Modeling of the Respiratory Depressant Effect of Norbuprenorphine in Rats

@article{Yassen2007PharmacokineticPharmacodynamicMO,
  title={Pharmacokinetic-Pharmacodynamic Modeling of the Respiratory Depressant Effect of Norbuprenorphine in Rats},
  author={Ashraf Yassen and Jingmin Kan and Erik Olofsen and Ernst Suidgeest and Albert Dahan and Meindert Danhof},
  journal={Journal of Pharmacology and Experimental Therapeutics},
  year={2007},
  volume={321},
  pages={598 - 607}
}
The objective of this investigation was to characterize the pharmacokinetic-pharmacodynamic (PK-PD) correlation of buprenorphine's active metabolite norbuprenorphine for the effect on respiration in rats. Following i.v. administration in rats (dose range 0.32–1.848 mg), the time course of the concentration in plasma was determined in conjunction with the effect in ventilation as determined with a novel whole-body plethysmography technique. The PK of norbuprenorphine was best described by a… Expand
Pharmacokinetic and pharmacodynamic modelling after subcutaneous, intravenous and buccal administration of a high-concentration formulation of buprenorphine in conscious cats
TLDR
The SC administration of Simbadol™ was characterized by prolonged absorption half-life and sustained plasma concentrations yielding long-lasting antinociception (≥ 24 hours) when compared with the IV and OTM routes. Expand
Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling.
TLDR
An overview of recent developments in incorporating receptor theory in PK-PD modeling with a specific focus on the identifiability of these models is provided. Expand
Pharmacokinetic and pharmacodynamic analysis in anesthesia : a modeling odyssey
TLDR
The development of an open source web application for Bland-Altman analysis of comparison data, which is able to take into account both intra- and interindividual variability is described. Expand
Reduced Pupil Diameter in Volunteers on Stable Buprenorphine Maintenance Therapy with Telaprevir: a Drug-Drug Interaction Involving P-Glycoprotein at the Blood-Brain Barrier?
TLDR
The BUP-related respiratory effects in mice were significantly increased in relation to reduced NBUP efflux at the BBB, with either P-glycoprotein pharmacological inhibition or gene disruption, supporting the notion that telaprevir and BUP/naloxone can be safely co administered. Expand
Pregnancy Increases Norbuprenorphine Clearance in Mice by Induction of Hepatic Glucuronidation
TLDR
The data suggest that the increased systemic CL of NBUP in pregnant mice is likely caused by an induction of hepatic Ugt expression and activity, and provides a basis for further mechanistic analysis of pregnancy-induced changes in the disposition ofNBUP and drugs that are predominately and extensively metabolized by Ugts. Expand
Mechanism-based pharmacodynamic modeling.
TLDR
In this chapter, commonly used mechanistic pharmacodynamic models are presented with respect to their important features, operable equations, and signature profiles and literature examples showcasing the utility of these models to adverse drug events are highlighted. Expand
P-Glycoprotein Is a Major Determinant of Norbuprenorphine Brain Exposure and Antinociception
TLDR
P-glycoprotein-mediated efflux influences brain access and antinociceptive, but not the respiratory, effects of norbuprenorphine. Expand
In Utero Exposure to Norbuprenorphine, a Major Metabolite of Buprenorphine, Induces Fetal Opioid Dependence and Leads to Neonatal Opioid Withdrawal Syndrome
TLDR
Findings support the possibility that NorBUP contributes to fetal opioid dependence and NOWS following maternal buprenorphine treatment during pregnancy, using a rat model of NOWS. Expand
Reduced Pupil Diameter in Volunteers on Stable Buprenorphine Maintenance Therapy with Telaprevir: a Drug-Drug Interaction Involving P-Glycoprotein at the Blood-Brain Barrier? L
TLDR
Although the interpretation of outpatient pupil diameter during the safety follow-up period could not be trusted since BUP is frequently misused by opioid abusers, it is believed that the decrease in pupil diameter observed at the study site 4 h after the coadministration of telaprevir and BUP/naloxone in comparison to BUP’s alone at 4 h postdoseonday1wasm isinterpreted. Expand
Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active.
TLDR
Both glucuronide metabolites of buprenorphine are biologically active at doses relevant to metabolite exposures, which occur after bupenorphine, and activity of the glucuronides may contribute to the overall pharmacology of buPrenorphines. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 58 REFERENCES
Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of the Respiratory-Depressant Effect of Buprenorphine and Fentanyl in Rats
TLDR
For fentanyl, unrealistically high estimates of the rate constants for receptor association and dissociation were obtained, indicating that hysteresis is caused solely by biophase distribution kinetics, consistent with fentanyl's fast receptor association/dissociation kinetics in vitro. Expand
Pharmacokinetic-Pharmacodynamic Modeling of the Antinociceptive Effect of Buprenorphine and Fentanyl in Rats: Role of Receptor Equilibration Kinetics
TLDR
The findings of this study show that the rate-limiting step in the onset and offset of buprenorphine's antinociceptive effect is distribution to the brain. Expand
Mechanism‐based PK/PD Modeling of the Respiratory Depressant Effect of Buprenorphine and Fentanyl in Healthy Volunteers
TLDR
Results show that for fentanyl hysteresis is entirely determined by the biophase distribution kinetics, whereas for buprenorphine hyste Respiratory depressant effect is caused by a combination of biophases distribution Kinetics and receptor association/dissociation kinetics. Expand
The comparative pharmacodynamics of remifentanil and its metabolite, GR90291, in a rat electroencephalographic model.
TLDR
Analysis of the data on the basis of a previously postulated, mechanism-based pharmacokinetic-pharmacodynamic model for synthetic opioids revealed that the low in vivo potency of GR90291 can be explained by a low affinity to the mu-opioid receptor in combination with a poor brain penetration. Expand
Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine.
We propose a model of drug pharmacodynamic response that when integrated with a pharmacokinetic model allows characterization of the temporal aspects of pharmacodynamics as well as theExpand
Characterization of the pharmacokinetics of buprenorphine and norbuprenorphine in rats after intravenous bolus administration of buprenorphine.
  • S. Gopal, T. Tzeng, A. Cowan
  • Chemistry, Medicine
  • European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  • 2002
TLDR
The present results suggest that the nonlinear disposition in the clearance and volume of distribution of BN can be attributed, in part, to the increasing concentration of the metabolite. Expand
Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine.
TLDR
The results suggest that the respiratory depression induced by NBN may be mediated by opioid mu receptors in the lung rather than in the brain, and that it is likely that buprenorphine-induced depression was rapidly reduced after i.v. administration. Expand
Buprenorphine is protective against the depressive effects of norbuprenorphine on ventilation.
TLDR
The data clearly show that norbuprenorphine alone causes important deleterious effects on ventilation in rats, and buprenorphin protective effect calls into question the role for norb uprenorphines in respiratory toxicity associated with bup Renorphine use. Expand
Pharmacokinetic analysis of enterohepatic circulation of buprenorphine and its active metabolite, norbuprenorphine, in rats.
TLDR
It was suggested that this increase in the proportion of NBN-Glu in bile observed after one enterohepatic cycling of BN may be due to the first-pass metabolism in the liver. Expand
Clinical actions of fentanyl and buprenorphine. The significance of receptor binding.
TLDR
Findings offer pharmacodynamic explanations for the differences in fentanyl and buprenorphine analgesic response profiles and suggest how binding interactions might be applied to therapeutic use. Expand
...
1
2
3
4
5
...